FDA Clears Prime Medicine’s IND Application For PM647, Investigational In Vivo Prime Editor For Alpha-1 Antitrypsin Deficiency

Prime Medicine, Inc. announced that the FDA has cleared its IND application for PM647, an investigational in vivo Prime Editor targeting Alpha-1 Antitrypsin Deficiency (AATD). This clearance allows the company to begin clinical studies in the U.S., where around 100,000 individuals are affected by the condition. Initial clinical data for PM647 is expected to be available in 2027, further building on the company's momentum following recent regulatory approvals for PM577a.